Evidence map›Paper›PMID 34694670›Full record

ReviewIET nanobiotechnology2021

Recent nanotheranostics applications for cancer therapy and diagnosis: A review.

Fahimeh Aminolroayaei, Daryoush Shahbazi-Gahrouei, Saghar Shahbazi-Gahrouei, Naser Rasouli

Open access · goldAbstract readReview
In one paragraph

Review in IET nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Recent nanotheranostic approaches in cancer research.Clinical and experimental medicine · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fahimeh AminolroayaeiDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Daryoush Shahbazi-GahroueiDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Saghar Shahbazi-GahroueiSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Naser RasouliDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IR

Funding

Deanship of Scientific Research at King Isfahan University of Medical Sciences 399018
6 · The paper itself

Abstract

Nanotheranostics has attracted much attention due to its widespread application in molecular imaging and cancer therapy. Molecular imaging using nanoparticles has attracted special attention in the diagnosis of cancer at early stages. With the progress made in nanotheranostics, studying drug release, accumulation in the target tissue, biodistribution, and treatment effectiveness are other important factors. However, according to the studies conducted in this regard, each nanoparticle has some advantages and limitations that should be examined and then used in clinical applications. The main goal of this review is to explore the recent advancements in nanotheranostics for cancer therapy and diagnosis. Then, it is attempted to present recent studies on nanotheranostics used as a contrast agent in various imaging modalities and a platform for cancer therapy.

Indexed as

NanoparticlesNeoplasmsHumansTheranostic NanomedicineTissue Distribution

Identifiers

PMID34694670
PMCPMC8675832
OpenAlexW3132700632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.